<?xml version="1.0" encoding="UTF-8"?>
<p id="Par67">Most of the other drugs such as JAK inhibitors, anti-IL-1, anti-IL-6, and anti-TNF agents are immunosuppressives, and these might interfere with the effective clearance of the virus at early phases of the disease. Thus, being on these drugs at the early phase of infection could be a disadvantage for rheumatology patients. On the other hand, these drugs might prevent the development of a cytokine storm, making a milder disease course possible. Currently, there is not enough data about COVID-19 disease course in patients with rheumatic diseases that are treated with biologic drugs (Table 
 <xref rid="Tab1" ref-type="table">1</xref>). In a survey study from Italy, Filocamo et al. reported that there was no confirmed COVID-19 case among 123 pediatric patients on biologic DMARDs for chronic rheumatic diseases [
 <xref ref-type="bibr" rid="CR156">156</xref>]. Current guidelines recommend continuing all immunosuppressive therapies providing disease control, and proper patient education against the virus.
</p>
